A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women
- PMID: 32864760
- DOI: 10.1111/ijd.15146
A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women
Abstract
Objective: To assess the efficacy and safety of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women. Topical 5% cysteamine is an antioxidant and tyrosinase inhibitor that has been shown to be effective in the treatment of melasma. However, to date, no study has compared the performance of topical cysteamine to hydroquinone for facial melasma.
Methods: A quasi-randomized, multicenter, evaluator-blinded clinical trial was conducted on 40 women with facial melasma who were submitted to the nightly application of 5% cysteamine (CYS) or 4% hydroquinone (HQ) on hyperpigmented areas for 120 days. Both groups were required to use tinted sunscreen (SPF 50; PPD 19). Subjects were assessed at the inclusion and after 60 and 120 days of treatment for mMASI, MELASQoL, and the difference in colorimetric luminosity between melasma and the adjacent unaffected skin. The Global Aesthetic Improvement Scale was used to assess the difference in the appearance of the skin through standardized photographs.
Results: The mean reduction of the mMASI scores was 24% for CYS and 41% for HQ (P = 0.015) at 60 days, and 38% for CYS and 53% for HQ (P = 0.017) at 120 days. The photographic evaluation revealed up to 74% improvement for both groups, without statistically significant difference between them (P = 0.087). The MELASQoL score showed a progressive decrease for both groups over time, despite the greater reduction for HQ after 120 days (P = 0.018). Colorimetric assessment disclosed progressive depigmenting in both groups, without statistically significant difference between them (P > 0.160). No severe adverse effects were identified in either group. Erythema and burning were the most important local adverse effects with cysteamine, although their frequency did not differ between groups (P > 0.170).
Conclusion: Cysteamine proved to be safe, well-tolerated, and effective, despite its inferior performance to hydroquinone in decreasing mMASI and MELASQoL in the treatment of melasma.
© 2020 the International Society of Dermatology.
Similar articles
-
Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial.J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1881-1887. doi: 10.1111/jdv.17344. Epub 2021 Jun 7. J Eur Acad Dermatol Venereol. 2021. PMID: 33988887 Clinical Trial.
-
Sequential therapy with topical clobetasol for 14 days followed by hydroquinone versus hydroquinone alone in facial melasma treatment: a randomized, double-blind, controlled clinical trial.Int J Dermatol. 2024 Feb 27. doi: 10.1111/ijd.17094. Online ahead of print. Int J Dermatol. 2024. PMID: 38411257
-
Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.Australas J Dermatol. 2021 Feb;62(1):e41-e46. doi: 10.1111/ajd.13432. Epub 2020 Sep 27. Australas J Dermatol. 2021. PMID: 32981068 Clinical Trial.
-
Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis.J Cosmet Dermatol. 2023 Apr;22(4):1168-1176. doi: 10.1111/jocd.15566. Epub 2022 Dec 25. J Cosmet Dermatol. 2023. PMID: 36566490 Review.
-
Efficacy of cysteamine and methimazole in treating melasma: A comparative narrative review.J Cosmet Dermatol. 2022 Sep;21(9):3867-3875. doi: 10.1111/jocd.15180. Epub 2022 Jul 19. J Cosmet Dermatol. 2022. PMID: 35751542 Review.
Cited by
-
The Impact of Antioxidants on Vitiligo and Melasma: A Scoping Review and Meta-Analysis.Antioxidants (Basel). 2023 Dec 6;12(12):2082. doi: 10.3390/antiox12122082. Antioxidants (Basel). 2023. PMID: 38136202 Free PMC article. Review.
-
Topical and Systemic Therapies in Melasma: A Systematic Review.Indian Dermatol Online J. 2023 Oct 27;14(6):769-781. doi: 10.4103/idoj.idoj_490_22. eCollection 2023 Nov-Dec. Indian Dermatol Online J. 2023. PMID: 38099013 Free PMC article. Review.
-
Update on Melasma-Part II: Treatment.Dermatol Ther (Heidelb). 2022 Sep;12(9):1989-2012. doi: 10.1007/s13555-022-00780-4. Epub 2022 Jul 29. Dermatol Ther (Heidelb). 2022. PMID: 35906506 Free PMC article. Review.
-
Evaluating the quality of life among melasma patients using the MELASQoL scale: A systematic review and meta-analysis.PLoS One. 2022 Jan 27;17(1):e0262833. doi: 10.1371/journal.pone.0262833. eCollection 2022. PLoS One. 2022. PMID: 35085327 Free PMC article.
References
-
- Handel AC, Lima PB, Tonolli VM, et al. Risk factors for facial melasma in women: a case-control study. Br J Dermatol 2014; 171: 588-594.
-
- McKesey J, Tovar-Garza A, Pandya AG. Melasma treatment: an evidence-based review. Am J Clin Dermatol 2020; 21: 173-225.
-
- Spierings NMK. Melasma: a critical analysis of clinical trials investigating treatment modalities published in the past 10 years. J Cosmet Dermatol 2020; 19: 1284-1289.
-
- Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol 2011; 65: 699-714.
-
- Pollo CF, Miot LDB, Meneguin S, et al. Factors associated with quality of life in facial melasma: a cross-sectional study. Int J Cosmet Sci 2018; 40: 313-316.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources